Nasarox (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nasarox, is an alpha‑adrenergic agonist presented as a nasal spray for topical nasal use. It relieves nasal congestion caused by the common cold, sinusitis and allergic rhinitis in adults and children over the recommended age. GNH USA supplies Nasarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nasarox, an alpha‑adrenergic agonist nasal decongestant, is used to alleviate congestion in several upper‑respiratory conditions. - Common cold: reduces nasal blockage and improves breathing. - Sinusitis: decreases mucosal swelling to ease sinus drainage. - Allergic rhinitis: alleviates congestion associated with allergic inflammation.

Nasal decongestants may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal mucosa. - Sneezing or mild itching. - Headache. - Transient taste disturbance. - Rebound congestion with prolonged use.

Serious or Rare Side Effects: - Elevated blood pressure. - Palpitations or tachycardia. - Severe nasal ulceration. - Allergic skin rash. - Hypertensive crisis (very rare). - Cardiac arrhythmias (rare).

Before using Nasarox, consider the following safety measures. - Do not exceed the recommended frequency: limit to one or two sprays per nostril every 12 hours. - Avoid use for more than three consecutive days to prevent rebound congestion. - Consult a healthcare professional if you are pregnant, planning pregnancy, or breastfeeding. - Use with caution in patients with hypertension, cardiovascular disease, diabetes, or thyroid disorders. - Do not use in children under six years of age unless directed by a physician. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline may interact with other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Concurrent use of other nasal decongestants: additive vasoconstriction may increase systemic effects.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible reduction in blood pressure control. - Beta‑blockers: may mask tachycardia symptoms. - Tricyclic antidepressants: potential for increased blood pressure.